Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test duo may flag sepsis in burn victims before symptoms worsen

NCT ID NCT07791030

Diagnosis Sponsor: Mansoura University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

Researchers at Mansoura University are testing whether two blood markers, procalcitonin and highly sensitive C-reactive protein, can detect sepsis early in people with major burns. The study will enroll 30 patients aged 3 to 65 with second or third degree burns. Blood samples are taken on admission and again after three days to see if rising levels of these markers signal an infection before it becomes severe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Measurement of procalcitonin and highly sensitive C-reactive protein levels in blood samples
What this could lead to
If these biomarkers prove reliable, doctors could spot sepsis in burn patients days earlier, potentially saving lives by starting treatment sooner.
What could go wrong
This is a small, early study with only 30 participants, so results may not apply to all burn patients. Also, these markers can rise for other reasons, which could limit their accuracy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Sep 2025

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is prospective study will include a total number of 30 patients with major burn. These patients will be admitted to Plastic, Reconstructive and Burn surgery center at Mansoura University from July 2025 to July 2026.

Ages

3 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from 3 years to 65 years. * Both sexes. * Patients with major burn (2nd and 3rd degrees of burn). Exclusion Criteria: * Patients with unrealistic expectations. * Patients with inhalational burn injury. * Patients with uncompensated chronic disease e.g. hepatic, renal. * Patients with mental or psychological troubles affecting the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burn sepsis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease burn

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Burn sepsis C-reactive protein Diagnostic role Early detection Highly sensitive Procalcitonin Prognostic role

Contacts and locations

Locations

  • Mansoura University

    Al Mansurah, Dakahlia Governorate, 35516, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.